The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 15.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Now in its fifth year, this symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever-increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state-of-the-art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
This activity is intended for Internists, Orthopedic Surgeons and Rheumatologists.
Following this activity, the participant will demonstrate the ability to:
- Discuss recent advances in the use of biologic agents in the treatment of rheumatoid arthritis
- Appreciate the unique challenges associated with transitioning the pediatric rheumatic disease patient into adult practice
- Discuss new and emerging issues in the management of gout
- Recognize the major issues related to the management of the pregnant rheumatic disease patient
- Recognize the major ophthalmologic manifestations of the rheumatic diseases
- Diagnose and manage common pulmonary manifestations of the rheumatic diseases
- Discuss current management approaches and controversies in the diagnosis and treatment of giant cell arthritis
Notice About Off-Label Use Presentations
The Johns Hopkins University School of Medicine/ Advances in the Diagnosis and Treatment of Rheumatic Diseases 2009 (EM) may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
Instructions to obtain a CME Certificate for this activity
You must register online at http://www.hopkinscme.edu/CourseDetail.aspx/80023077 . A certificate processing fee of $35 will be required at the time of registration. Once registered, you will be required to complete the Activity Evaluation, and then you can take the post test.
Release Date: August 10, 2009
Expiration Date: August 9, 2011
Policy on Speaker and PROVIDER Disclosure
It is the policy of The Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
|Michael Becker, MD||Consultant: Proctor & Gamble, Novartis, Regeneron, Savient, Takeda|
|William Bishai, MD, PhD||Honorarium: Abbott, Schering-Plough|
|Ellen Ginzler, MD, MPH||Grants/Research Support: Aspreva, Bristol-Myers Squibb, Human Genome Sciences, Merck/Serono, UCB|
Consultant: Genentech, MedImmune, Zymogenetics
|Nancy Lane, MD||Grants/Research Support: Nordic Biosciences, Pfizer, Proctor & Gamble|
Consultant: Pfizer, UCB, Zosano Pharma
Speaker Bureau: Eli Lilly
|Peter Merkel, MD, MPH||Grants/Research Support: Actelion, American College of Rheumatology, Biovitrum, Bristol-Myers Squibb, Celgene, Cipher, Cystic Fibrosis Foundation, Encysive, European League Against Rheumatism, Genentech, Genzyme, National Institutes of Health, Novartis, Scleroderma Foundation, US Food and Drug Adminstration, The Vasculitis Foundation|
|Larry Moreland, MD||Grants/Research Support: Pfizer, Incyte, Serono|
Consultant: Biogen, Pfizer, Incyte, Kalobios, Lilly, UCB
Honorarium: Biogen, Pfizer, Incyte, Kalobios, Lilly, UCB
|Kenneth Saag, MD, MSc||Grants/Research Support: Amgen, GlaxoSmithKline, Lilly, Novartis, Roche, Sanofi-aventis|
Consultant: Amgen, Lilly, Merck, Novartis, Proctor & Gamble, Roche, Sanofi-aventis
Honorarium: Amgen, Lilly, Merck, Novartis, Proctor & Gamble, Roche, Sanofi-aventis
Speaker Bureau: Novartis
All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
|Michael Becker, MD||anakinra, pegloticase, rilonacept|
|Megan Clowse, MD, MPH||aspirin, cortocosteroids, NSAID, polyhydroxy chloroquine, sulfasalazine, TNF inhibitors|
– all use during pregnancy
|James Dunn, MD||immunosupressive drugs for ocular inflammatory diseases|
|Ellen Ginzler, MD, MPH||abatacept, anti-interferon alpha and beta, atacicept, azathioprine, belimumab, cyclosporine, cyclophosphamide, epratuzumab, leflunomide, MabThera, mycophenolate mofetil, tacrolimus, mycophenolic acid, ocrelizumab, rituximab, thalidomide, tocilizumab|
|Sergio Jimenez, MD||CellCept (mycophenolate mofetil), cytoxan (cyclophosphamide), Gleevec (imatinib)|
|Nancy Lane, MD||Phase II clinical trial of a nerve growth factor inhibitor|
|Stuart Levine, MD||azathioprine, cyclophosphamide- vasculitis, methotrexate- vasculitis|
|Peter Merkel, MD, MPH||abatacept, anti-IL-6, Anti-TNF, alpha agents, aspirin, azathioprine, cyclophosphamide, cyclosporin, glucocorticoids, methotrexate, mycophenolate|
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
Now in its fifth year, this two-day symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever-increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state-of-the-art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
Date: May 15-16, 2009
Don’t have SilverLight? Get it here.
Click on a Link Below to Begin the Lecture
- Ankylosing Spondylitis: New Developments
- Ankylosing Spondylitis: What Does MRI Tell Us About Pathology?
- Biologic DMARDs and Infection Risk
- Fracture Risk Assessment
- Inflammatory Arthritis Panel Discussion
- Knee Replacement Therapy
- Management of the Pregnant Rheumatic Disease Patient
- Metabolic Syndrome: Assessing CV Risk
- Non-pharmacologic Approaches and Support for the Patient with Arthritis
- Ocular Manifestations of the Rheumatic Diseases
- Osteoarthritis Update
- Practical Pulmonology for the Rheumatologist
- Pulmonary Hypertension in Scleroderma
- Scleroderma: Update on Treatment
- SLE: Latest News on Treatment
- Topics in the Managment of Gout
- Transitioning the Pediatric Patient to Adult Practice – (partial recording)
- Treating RA 2009: Too Many Choices? – (partial recording)
- Update in the Management of Giant Cell Arteritis
- Vasculitis Grab Bag
Policy On Speaker And Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.